Background and Purpose-Little is known of the excess risk attributable to secondary carotid angioplasty and stenting (CAS). This study evaluates outcomes of redo-CAS and CAS after prior ipsilateral carotid endarterectomy (CASAPICEA) relative to primary-CAS. Methods-We studied all patients in the Vascular Quality Initiative, who underwent primary-CAS, CASAPICEA, or redo-CAS (2003 
T he number of patients treated with carotid angioplasty and stenting (CAS) has increased over the years in the United States. [1] [2] [3] Equipoise exists between carotid endarterectomy (CEA) and CAS on multiple fronts, and the superiority or equivalence of these treatments remains a subject of intense debate. [4] [5] [6] Despite this, studies have shown outcomes after CAS for the treatment of de novo disease fall within acceptable range when performed by experienced interventionists. 7 Restenosis is a recognized complication of carotid revascularization. Results from the CREST (Carotid Revascularization Endarterectomy versus Stenting Trial) revealed a restenosis rate of 6.3% after CEA and 6% after CAS at 2 years and 9.7% versus 12.2% at 10 years, respectively. 4, 8 That randomized trial also showed that restenosis after prior CEA or CAS is associated with a 4-fold increase in the risk for stroke. Hence, the need for reintervention in patients with hemodynamically significant disease. 8 The contemporary role of CAS has expanded to include treatment of restenosis in patients with prior ipsilateral CEA or CAS. The inherent risk of restenosis implies that the number of patients who undergo CAS after prior ipsilateral carotid endarterectomy (CASAPICEA) and redo-CAS will increase over time.
Redo-CAS and CASAPICEA differ biologically from CAS for de novo disease. Little is known of the outcomes of CAS performed on the background of prior carotid intervention relative to CAS performed for primary disease. Hence, the objective of this study is to evaluate outcomes of redo-CAS and CASAPICEA relative to primary-CAS. We will also identify predictors of adverse outcomes in each treatment group. These results will provide useful information to patients and their interventionists for planning and prognostication when the need for secondary ipsilateral intervention arises.
Methods
We performed a retrospective analysis of all patients in the Vascular Quality Initiative who underwent primary-CAS; or CAS after prior ipsilateral CEA; or CAS after prior ipsilateral CAS between January 1, 2003, and September 30, 2016. The Vascular Quality Initiative is a prospectively maintained database of the Society for Vascular Surgery for patient safety and quality improvement purposes. Details of the data collection and validation process have been published previously. 9 The current study was approved by the Vascular Quality Initiative Research Advisory Committee, and the Johns Hopkins Institutional Review Board waived the need for individual patient consent.
Patients who underwent primary or secondary CAS were identified directly from variables recorded in the Vascular Quality Initiative database. Symptomatic status was defined as the occurrence of ipsilateral stroke, transient ischemic attack, or amaurosis fugax within 6 months before treatment. Stroke was defined as the occurrence of minor or major, ocular or cortical stroke after surgery/intervention. Myocardial infarction was a clinical or ECG confirmed diagnosis or an elevation in troponins. Pertinent complications include new bradycardia requiring treatment with medication or pacer. Arrhythmia was a new rhythm disturbance requiring treatment with medications or cardioversion. Hypertension and hypotension were defined by the need for treatment with intravenous medication, that is, continuous intravenous infusion or >1 dose required >1 hour after surgery.
Statistical Methods
Descriptive analyses of the study groups were performed using χ 2 and ANOVA. Kaplan-Meier (KM) estimates were computed, and log-rank tests were applied to compare the survival function between the treatment groups. Univariable and multivariable logistic and Cox regression methods were used to analyze the 30-day and 1-year outcomes and identify their predictors. Variables included in the multivariate model were based on the univariable analysis, prior literature, guidance of likelihood ratio tests, and Akaike information indices with a goal to achieve model parsimony. All analyses were performed using Stata 14.1 statistical software (StataCorp, College Station, TX), and statistical significance was accepted at P<0.05.
Results

Patient Characteristics
There were 11 742 CAS procedures studied. Of which, 8519 (72%) were primary-CAS, 2645 (23%) were performed after prior ipsilateral CEA, while 578 (5%) were redo-CAS. The majority of patients underwent CAS for asymptomatic disease and ipsilateral stenosis >80% ( Table 1 ). The majority of CAS procedure were performed under elective conditions, local anesthesia, and via the transfemoral approach ( 
30-Day Postoperative Outcomes
Overall, 237 (2%) patients experienced ipsilateral stroke within 30 days of the procedure. Of these, 186 (2.2%) occurred after primary-CAS, 41 (1.6%) occurred after CASAPICEA, while 10 (1.7%) occurred after redo-CAS (P=0.11). There was no difference in 30-day stroke between the groups stratified by preprocedural symptoms (Table 2 ). There was no statistical difference in the absolute rates of myocardial infarction, mortality, stroke/death, stroke/death/myocardial infraction among asymptomatic patients in the treatment groups within 30 days (Table 2) . Thirty-day mortality was higher for primary-and redo-CAS as was the composite of stroke/death and stroke/death/myocardial infraction relative to CASAPICEA. The absolute rates of arrhythmia 2.7% versus 1.5% versus 1.6% (P=0.001), bradycardia 12.3% versus 4.5% versus 6.6% (P<0.001), and hypotension 17.5% versus 7.7% versus 10.9% (P<0.001) were higher for primary-CAS relative to CASAPICEA and redo-CAS (Table 3) . Conversely, hypertension was least for primary-CAS: 8.6% versus 12.1% versus 12.3% (P<0.001).
The multivariable logistic regression analyses revealed no significant difference in the odds of 30-day postoperative stroke in the overall cohort, as well as the sub cohorts of symptomatic and asymptomatic patients (Table II in the online-only Data Supplement). In contrast, the odds of the composite of stroke/ death at 30 days among symptomatic patients were significantly lower for CASAPICEA (odds ratio: 0.60; 95% CI: 0.37-0.98; P=0.04) compared with primary-CAS. Risk-adjusted analyses confirmed the significantly lower odds of bradycardia and hypotension in the CASAPICEA and redo-CAS groups compared with primary-CAS (Table III in the online-only Data Supplement). Conversely, the odds of hypertension were significantly higher for CASAPICEA (odds ratio: 1.66; 95% CI: 1.43-1.94; P<0.001) and redo-CAS (odds ratio: 1.55; 95% CI: 1.18-2.05; P=0.002) compared with primary-CAS. The significant predictors of 30-day stroke/death for primary-CAS were older age, preoperative symptoms, diabetes mellitus, chronic obstructive pulmonary disease, ASA class IV or V (American Society of Anesthesiologists), urgent or emergent procedure, nonuse of protective device, and placement of 2 stents (Table IV in the online-only Data Supplement). The predictors of 30-day stroke/death for CASAPICEA were urgent or emergent procedure and placement of 2 stents. The predictors of 30-day stroke/ death for redo-CAS were increasing age, male gender, symptomatic status, ASA class IV, and urgent and emergent procedures.
One-Year Outcomes
Overall, there were 302 (2.6%) ipsilateral stroke events within 1 year. Of these, 229 (2.7%) occurred after primary-CAS, 60 (2.3%) after CASAPICEA, and 13 (2.2%) occurred after redo-CAS (P=0.42). Unadjusted KM estimates of freedom from stroke at 1 year were 95.0% (95% CI: 94.3-95.7) for primary, 96.2% (95% CI: 95.1-97.1) for CASAPICEA, and 96.4% (95% CI: 93.7-98.0) for redo-CAS (P=0.004). Freedom from stroke was 97% (primary-CAS: 96.8%; CASAPICEA: 97.1%; redo-CAS: 97.1%; P=0.77) for asymptomatic patients and 93% (primary-CAS: 92.5%; CASAPICEA: 94.5%; redo: 95.1%; P=0.22) for symptomatic patients. The risk-adjusted analyses showed that there was no significant difference in freedom from stroke for CASAPICEA (P=0.17) and redo-CAS (P=0.72) compared with primary-CAS in the overall cohort, as well as subcohorts of asymptomatic and symptomatic patients (Table II in KM estimates of mortality at 1 year were 6.3% (95% CI: 5.8-6.9) for primary-CAS, 5% (95% CI: 4.2-6.09) for CASAPICEA, and 6.2% (95% CI: 8.6-4.4) for redo-CAS (P=0.02). The risk-adjusted analyses showed no significant difference in 1-year mortality in the CASAPICEA (P=0.80) and redo-CAS (P=0.26) groups compared with primary-CAS. One-year mortality was higher for symptomatic (aHR: 1.17; 95% CI: 1.03-1.32; P=0.02) compared with asymptomatic patients.
The absolute stroke/death rate over the study period was 12.5% (primary: 12.8%; CASAPICEA: 11.3%; redo-CAS: 12.8%; P=0.09). Unadjusted KM estimates of stroke/death at 1 year was 8.5% (95% CI: 7.9-9.1) for primary-CAS, 6.9% (95% CI: 5.9-7.9) for CASAPICEA, and 8.5% (95% CI: 7.9-9.1) for redo-CAS (P=0.003). The unadjusted KM estimates of freedom from stroke/death were highest for CASAPICEA in the strata of asymptomatic ( Figure 1 
Discussion
The number of patients who undergo CAS for de novo carotid disease, restenosis after prior CEA, and in stent restenosis is increasing in the United States. Variance in the biological mileu for CAS in the above scenarios suggests that differences might exist in their outcomes and complications. Little has been reported about these differences before now. The majority of patients who underwent primary-, CASAPICEA, and redo-CAS were asymptomatic. The prevalence of preprocedural symptoms is in tandem with the indications for CAS and the proportions of patients who undergo treatment for carotid stenosis in the general and high-risk US population as previously reported. [10] [11] [12] [13] Preoperative symptoms are not entirely benign because in many patients, the first symptom of carotid stenosis is a stroke. In this study, >50% of symptomatic primary-CAS patients presented with a stroke. The occurrence of preprocedural symptoms is also associated with worse outcomes as has 
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been shown in this study and others. 14, 15 Carotid revascularization especially with CAS in asymptomatic patients remains the subject of fierce debate, and the aforementioned points have been cited by proponents of carotid interventions in asymptomatic patients. 16 It is generally accepted that restenosis >70% constitutes significant impairment to carotid blood flow based on the 4-fold increase in the risk of ipsilateral stroke associated with restenosis >70% found in the Carotid Revascularization Endarterectomy versus Stenting Trial. 8 The majority of cases in this review were performed for patients with degree of ipsilateral stenosis exceeding 70%. Consensus is lacking on the constituent duplex velocity criteria for hemodynamically significant post-CAS restenosis. Consequently, it is recommended that suspicions of post-CAS restenosis on duplex should be confirmed using digital subtraction angiography before treatment. 17 Our results show that CAS is not without risks in all groups of patients studied. Our findings of 2.2% stroke and 1.8% mortality within 30 days of primary-CAS are similar to those from cohort studies and randomized trials that have reported outcomes in the range of 1.1 to 5.2 for 30-day stroke and 0.1 to 4.6 for 30-day mortality. 4, 12, 18 In a prior comparison of CASAPICEA and primary-CAS, other investigators evaluated 68 primary-CAS and 112 CASAPICEA patients. 19 They reported 30-day stroke of 16% for symptomatic primary-CAS patients, 2% for symptomatic CASAPICEA, but no stroke in the asymptomatic group. Their 16% stroke rate significantly exceeds the 3.1% rate reported in the current study. However, their 30-day stroke rate of 2% for CASAPICEA is similar to our report of 1.9% in the current study. In contrast to our study, the prior report did not include risk-adjusted comparisons between the treatment groups. 19 The results from the National Cardiovascular Data Registry also showed no significant difference in the composite end points between the redo and primary intervention groups at 30 days. 20 The rates of stroke/death reported from this study fall within the intersocietal guidelines for the treatment of carotid disease based on the risks of asymptomatic disease progression. 17, 21, 22 Answers to questions relating to the benefit of intervention relative to optimal medical therapy are also anticipated from ongoing randomized trials.
Multiple studies have reported no significant difference in the outcomes of CEA versus CAS for the treatment of post-CEA restenosis and in stent restenosis. 6, 23, 24 When the need to perform secondary CAS arises, we have shown that CASAPICEA is associated significantly lower perioperative stroke/death relative to primary-CAS. The stability of lesions treated might contribute to this difference. One might be tempted to extrapolate that CASAPICEA is safer than redo CEA for post-CEA restenosis. Such a conclusion will require a matched cohort of redo CEA and CASAPICEA patients as has been done elsewhere. 6, 23 The relative impact of CASAPICEA and redo-CAS on periprocedural heart rate and blood pressure despite adjustment for preoperative medication use as shown in this study is remarkable. The effect of angioplasty and stenting on the carotid reflex and the physiological adaptations over time are well-known. [25] [26] [27] [28] [29] It is possible that prior surgical dissection of the carotid sinus with CEA and adaptations from prior CAS blunt the carotid reflex in patients who undergo CASAPICEA and redo-CAS, respectively. This might explain the decreased likelihood of hypotension and bradycardia but higher propensity of hypertension among these patients compared primary-CAS as we have shown. Investigators from the International Carotid Stenting Study showed that hemodynamic disturbances were associated with the occurrence of periprocedural stroke in 33% of patients who underwent CAS, and this association has been echoed by others. 30, 31 These highlight the clinical significance of the findings of the current study and the need for providers to anticipate and mitigate these hemodynamic events as they occur, in line with the ongoing aim to further lower the procedural risk associated with carotid revascularization. Based on data from a limited number of patients, some authors recommend prophylactic use of atropine to prevent intraoperative bradycardia and cardiac morbidity during CAS. 32 We do not have information on prophylactic atropine use and its impact on these population-based outcomes. The benefit of prophylactic atropine use reported from institutional experience deserves further validation at population levels. The patient characteristics identified as predictors of adverse events in this study are in tandem with prior studies. 11, 14, 33 They underscore the importance of preprocedural risk assessment, anticipation, prompt recognition, and rescue of at-risk patients. We have shown that CAS performed under urgent or emergent conditions is associated with 2-to 5-fold increase in risk of perioperative stroke/death. The need for urgent or emergent intervention likely signify patient presentations that are associated with poor outcomes ab initio. The association between urgent/emergent procedure and adverse outcomes was persistent with and without adjustment for preprocedural symptoms. Another difference between procedures performed urgently/emergently versus those performed under elective conditions is preoperative planning. Adequate planning ensures that optimal human and material resources are available to intervene at the earliest sign of a potential adverse event in a timely manner. Consequently, the benefits of planned procedures cannot be overstated. In this study, placement of 2 carotid stents was associated with a 2-fold increase in adverse outcome. In view of the myriad of stent types and lengths currently available, we recommend the use of a single carotid stent of appropriate length to cover the lesion and mitigate this undesirable effect. Some studies have shown benefit associated with the use of cerebral protection devices [34] [35] [36] while others have reported worse outcome with their use. 37 In this study, the use of cerebral protection device was protective for primary-CAS but not CASAPICEA or redo-CAS (Table IV in the online-only Data Supplement).
We acknowledge that this study is limited in its retrospective design, and it contains data up to 1 year. As such, our findings might not be generalizable beyond that time point. We do not have data on the duration between first carotid intervention and the index CAS. Hence, we cannot evaluate the impact of intimal hyperplasia versus atherosclerosis on outcomes. We are unable to differentiate redo-CAS performed for in stent restenosis from that performed for extension of atherosclerotic plaque. Although this difference in lesion pathogenesis attracts technical considerations, it does not change the fact that the redo procedure involves placing a stent in a previously stented carotid artery. 38 In either case, overlap likely exists. We opine that different pathogenesis of the secondarily treated lesion has little impact on the outcomes that we have reported, but this is left to be proven in a study capable of such discrimination. Carotid artery flow velocities are unavailable in this study. It is also likely that patients who underwent redo-CAS might have failed prior balloon angioplasty. We do not have information on these prior interventions, hence, we cannot determine their impact on outcomes. It is recommended that patients receive dual antiplatelet therapy at least 48 hours before CAS and that activated clotting times of 250 to 300 seconds are achieved before lesion manipulation. 39, 40 This study does not take the dose or relative timing of administration of antiplatelet and anticoagulant medications into consideration. Despite these limitations, this study is novel in its evaluation of contemporary event rates and relative outcomes for primary-CAS, CASAPICEA, and redo-CAS.
Conclusions
We have shown absolute and composite event rates after primary-CAS, CASAPICEA, and redo-CAS. There is no significant difference in stroke, death, and stroke/death among asymptomatic patients in the treatment groups. CASAPICEA is associated with significantly lower odds of stroke/death compared with primary-CAS among symptomatic patients. CASAPICEA and redo-CAS are associated with significantly lower odds of hypotension and bradycardia but higher odds of hypertension compared with primary-CAS. There are no significant differences in 1-year stroke, death, and stroke/ death between primary-CAS, CASAPICEA, and redo-CAS. These results provide useful information to providers and patients for prognostic purposes when the need for secondary CAS arises.
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